A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis

Trial Profile

A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Osteoporosis
  • Focus Pharmacodynamics; Registrational
  • Sponsors Pfenex
  • Most Recent Events

    • 09 Aug 2017 According to a Pfenex media release, the company expects to submit the new drug application (NDA) in the third quarter of 2018 to the FDA.
    • 09 Aug 2017 According to a Pfenex media release, the enrollment of the study is approaching completion and interim pharmacokinetic data from this study is expected in the second half of 2017.The immunogenicity data is expected in the first half of 2018.
    • 08 May 2017 According to a Pfenex media release, the company expects to complete the enrollment in this study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top